Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sa Wang

Showing results (201-210 of 215) with videos related to

Pageof 22
Sort By:
Cancer|June 1, 2016
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesGevorg N Tamamyan, Hagop M Kantarjian, Jing Ning, et al.
Medicine|August 16, 2019
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48Rong-Yue Liang, Jing-Hang Xu, Chong-Wen Si, et al.
The Lancet. Haematology|August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialTapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
American Journal of Hematology|May 15, 2016
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimenMichael E Rytting, Elias J Jabbour, Jeffrey L Jorgensen, et al.
American Journal of Hematology|August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Matteo Molica, et al.
Nature Communications|October 31, 2020
Genomic surveillance of COVID-19 cases in BeijingPengcheng Du, Nan Ding, Jiarui Li, et al.
Virchows Archiv : an International Journal of Pathology|February 23, 2024
Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agentsMario L Marques-Piubelli, Bijender Kumar, Rafet Basar, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.
Pageof 22

Showing results (201-210 of 215) with videos related to

Sort By:
Pageof 22
Cancer|June 1, 2016
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesGevorg N Tamamyan, Hagop M Kantarjian, Jing Ning, et al.
Medicine|August 16, 2019
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48Rong-Yue Liang, Jing-Hang Xu, Chong-Wen Si, et al.
The Lancet. Haematology|August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialTapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
American Journal of Hematology|May 15, 2016
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimenMichael E Rytting, Elias J Jabbour, Jeffrey L Jorgensen, et al.
American Journal of Hematology|August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Matteo Molica, et al.
Nature Communications|October 31, 2020
Genomic surveillance of COVID-19 cases in BeijingPengcheng Du, Nan Ding, Jiarui Li, et al.
Virchows Archiv : an International Journal of Pathology|February 23, 2024
Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agentsMario L Marques-Piubelli, Bijender Kumar, Rafet Basar, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.
Pageof 22